AP2011005978A0 - 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. - Google Patents

2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.

Info

Publication number: AP2011005978A0
Authority: AP; ARIPO
Prior art keywords: diaminopyrimidines; excessive; treatment; cell proliferation; abnormal cell
Prior art date: 2009-05-29

Application number

AP2011005978A

Other languages

English (en)

Inventor

Daniel Kuhn

Ioannis Sapountzis

Heinz Stadtmueller

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-29

Filing date

2010-05-28

Publication date

2011-12-31

2010-05-28 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2011-12-31 Publication of AP2011005978A0 publication Critical patent/AP2011005978A0/xx

Links

230000002159 abnormal effect Effects 0.000 title 1
230000004663 cell proliferation Effects 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AP2011005978A 2009-05-29 2010-05-28 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. AP2011005978A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09161496		2009-05-29
EP10161628		2010-04-30
PCT/EP2010/057408 WO2010136559A1 (fr)	2009-05-29	2010-05-28	2, 4-diaminopyrimidines pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale

Publications (1)

Publication Number	Publication Date
AP2011005978A0 true AP2011005978A0 (en)	2011-12-31

Family

ID=42289495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2011005978A AP2011005978A0 (en)	2009-05-29	2010-05-28	2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.

Country Status (22)

Country	Link
US (1)	US8410126B2 (fr)
EP (1)	EP2435411B1 (fr)
JP (1)	JP5756799B2 (fr)
KR (1)	KR20120135010A (fr)
CN (1)	CN102448943A (fr)
AP (1)	AP2011005978A0 (fr)
AR (1)	AR076620A1 (fr)
AU (1)	AU2010251943A1 (fr)
BR (1)	BRPI1014994A2 (fr)
CA (1)	CA2763700A1 (fr)
CL (1)	CL2011003022A1 (fr)
CO (1)	CO6470899A2 (fr)
EA (1)	EA201101674A1 (fr)
EC (1)	ECSP11011558A (fr)
IL (1)	IL216084A0 (fr)
MA (1)	MA33302B1 (fr)
MX (1)	MX2011012643A (fr)
PE (1)	PE20120370A1 (fr)
SG (1)	SG176599A1 (fr)
TW (1)	TW201107308A (fr)
UY (1)	UY32673A (fr)
WO (1)	WO2010136559A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2054392A2 (fr) *	2006-06-15	2009-05-06	Boehringer Ingelheim International GmbH	2-anilino-4-(hétérocyclique)amino-pyrimidines comme inhibiteurs de proteine kinase c-alpha
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
EP2300013B2 (fr)	2008-05-21	2024-11-13	Takeda Pharmaceutical Company Limited	Dérivés phosphorés servant d'inhibiteurs de kinase
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US20130324532A1 (en)	2011-02-17	2013-12-05	Cancer Therapeutics Crc Pty Limited	Fak inhibitors
AU2012216894B2 (en)	2011-02-17	2016-07-14	Cancer Therapeutics Crc Pty Limited	Selective FAK inhibitors
EP2704572B1 (fr)	2011-05-04	2015-12-30	Ariad Pharmaceuticals, Inc.	Composés permettant d'inhiber la prolifération cellulaire dans les cancers induits par l'egfr
JP6469567B2 (ja)	2012-05-05	2019-02-13	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
EP3475263B1 (fr)	2016-06-27	2022-12-28	Rigel Pharmaceuticals, Inc.	Composés de 2,4-diaminopyrimidine et leur utilisation comme inhibiteurs de irak4
KR20190114910A (ko) *	2018-03-30	2019-10-10	한미약품 주식회사	상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
EP3966207B1 (fr)	2019-05-10	2023-11-01	Deciphera Pharmaceuticals, LLC	Phénylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
EP3966206B1 (fr)	2019-05-10	2023-08-09	Deciphera Pharmaceuticals, LLC	Hétéroarylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
KR20220012866A (ko) *	2019-05-23	2022-02-04	코르테바 애그리사이언스 엘엘씨	살진균성 아릴 아미딘
JP7626722B2 (ja)	2019-06-17	2025-02-04	デシフェラ・ファーマシューティカルズ，エルエルシー	アミノピリミジンアミドオートファジー阻害剤およびその使用方法
JP2024511681A (ja) *	2021-04-02	2024-03-14	ブリッジバイオセラピューティクスインコーポレイテッド	Ｎ２－フェニルピリミジン－２，４－ジアミン化合物ならびにその調製方法及び使用方法
WO2024253476A1 (fr) *	2023-06-09	2024-12-12	주식회사 에스트리온	Composition pharmaceutique pour la prévention ou le traitement d'une tumeur cérébrale

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6008101A (en) *	2000-05-22	2001-12-03	Leo Pharm Prod Ltd	Benzophenones as inhibitors of il-1beta and tnf-alpha
WO2003030909A1 (fr)	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
DK1438053T3 (da) *	2001-10-17	2008-12-08	Boehringer Ingelheim Pharma	Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
EP1518855B1 (fr) *	2002-06-28	2011-10-26	Astellas Pharma Inc.	Derive de diaminopyrimidinecarboxamide
EA013248B1 (ru) *	2002-12-20	2010-04-30	Пфайзер Продактс Инк.	Производные пиримидина для лечения патологического роста клеток
US7109337B2 (en)	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
CN102127058A (zh) *	2004-05-14	2011-07-20	辉瑞产品有限公司	治疗异常细胞生长的嘧啶衍生物
US20070032514A1 (en) *	2005-07-01	2007-02-08	Zahn Stephan K	2,4-diamino-pyrimidines as aurora inhibitors
US8623887B2 (en)	2006-05-15	2014-01-07	Boehringer Ingelheim International Gmbh	Compounds
ATE497496T1 (de) *	2006-10-19	2011-02-15	Rigel Pharmaceuticals Inc	2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
KR20100132550A (ko) *	2008-04-16	2010-12-17	포톨라 파마슈티컬스, 인코포레이티드	ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
US8138339B2 (en) *	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases

2010
- 2010-05-21 US US12/784,813 patent/US8410126B2/en active Active
- 2010-05-28 PE PE2011002012A patent/PE20120370A1/es not_active Application Discontinuation
- 2010-05-28 BR BRPI1014994A patent/BRPI1014994A2/pt not_active Application Discontinuation
- 2010-05-28 EP EP10724385.9A patent/EP2435411B1/fr active Active
- 2010-05-28 WO PCT/EP2010/057408 patent/WO2010136559A1/fr not_active Ceased
- 2010-05-28 EA EA201101674A patent/EA201101674A1/ru unknown
- 2010-05-28 CN CN2010800234907A patent/CN102448943A/zh active Pending
- 2010-05-28 MX MX2011012643A patent/MX2011012643A/es not_active Application Discontinuation
- 2010-05-28 AU AU2010251943A patent/AU2010251943A1/en not_active Abandoned
- 2010-05-28 KR KR1020117031173A patent/KR20120135010A/ko not_active Withdrawn
- 2010-05-28 JP JP2012512388A patent/JP5756799B2/ja active Active
- 2010-05-28 SG SG2011086790A patent/SG176599A1/en unknown
- 2010-05-28 AP AP2011005978A patent/AP2011005978A0/xx unknown
- 2010-05-28 CA CA2763700A patent/CA2763700A1/fr not_active Abandoned
- 2010-05-28 MA MA34394A patent/MA33302B1/fr unknown
- 2010-05-28 TW TW099117275A patent/TW201107308A/zh unknown
- 2010-05-28 AR ARP100101883A patent/AR076620A1/es unknown
- 2010-05-28 UY UY0001032673A patent/UY32673A/es not_active Application Discontinuation
2011
- 2011-11-01 IL IL216084A patent/IL216084A0/en unknown
- 2011-11-29 CL CL2011003022A patent/CL2011003022A1/es unknown
- 2011-12-15 CO CO11173252A patent/CO6470899A2/es not_active Application Discontinuation
- 2011-12-27 EC EC2011011558A patent/ECSP11011558A/es unknown

Also Published As

Publication number	Publication date
JP5756799B2 (ja)	2015-07-29
BRPI1014994A2 (pt)	2016-05-03
WO2010136559A1 (fr)	2010-12-02
JP2012528121A (ja)	2012-11-12
EA201101674A1 (ru)	2012-06-29
TW201107308A (en)	2011-03-01
CN102448943A (zh)	2012-05-09
UY32673A (es)	2010-12-31
CL2011003022A1 (es)	2012-07-13
AR076620A1 (es)	2011-06-22
AU2010251943A1 (en)	2011-12-01
SG176599A1 (en)	2012-01-30
CA2763700A1 (fr)	2010-12-02
US20110130401A1 (en)	2011-06-02
MX2011012643A (es)	2011-12-14
IL216084A0 (en)	2012-01-31
EP2435411B1 (fr)	2014-10-29
US8410126B2 (en)	2013-04-02
PE20120370A1 (es)	2012-05-09
EP2435411A1 (fr)	2012-04-04
KR20120135010A (ko)	2012-12-12
MA33302B1 (fr)	2012-05-02
ECSP11011558A (es)	2012-01-31
CO6470899A2 (es)	2012-06-29

Publication	Publication Date	Title
IL216084A0 (en)	2012-01-31	2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
IL260117A (en)	2018-07-31	Use of placental cells to treat diseases, syndromes or conditions of the lungs
MY173616A (en)	2020-02-11	Compositions and methods for lowering triglycerides
WO2010058032A3 (fr)	2010-07-15	Nouveaux composés
AP2010005508A0 (en)	2010-12-31	Triazole derivatives useful for the treatment of diseases.
PL2346864T3 (pl)	2013-08-30	Nowe związki użyteczne do leczenia chorób degeneracyjnych i zapalnych
MY160241A (en)	2017-02-28	5-alkynyl-pyrimidines
IL230635A (en)	2015-11-30	An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
IN2012DN02471A (fr)	2015-08-21
ZA201201222B (en)	2022-11-30	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivatives,methods for the production thereof and use thereof for treating diseases
ZA201005384B (en)	2011-10-26	Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta
AP2011005857A0 (en)	2011-10-31	Tablets for combination therapy.
MX2009009190A (es)	2009-09-04	Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
IL201562A0 (en)	2010-05-31	Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
WO2010012745A3 (fr)	2010-07-22	Benzimidazoles
TN2011000531A1 (en)	2013-05-24	5- alkynyl - pyridines
UA103197C2 (uk)	2013-09-25	Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
IN2012DN01846A (fr)	2015-08-21
NZ609924A (en)	2015-02-27	Porphyrin treatment of neurodegenerative diseases
WO2010083240A9 (fr)	2010-11-04	Procédés pour le traitement de troubles inflammatoires au moyen de composés de la 2,4-pyrimidine diamine
EP2387565A4 (fr)	2012-07-11	Composés de la 2,4-pyrimidine diamine pour le traitement de troubles inflammatoires
SI2473492T1 (sl)	2016-01-29	Postopek za pripravo(1S,4R)-2-oksa-3-azabiciklo(2.2.1)hept-5-enov
AP2011005893A0 (en)	2011-10-31	Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
TN2011000049A1 (en)	2012-09-05	5-alkynyl-pyrimidines
TN2010000463A1 (en)	2012-05-24	Compositions and methods for preparing and using same